CPC G01N 33/57492 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); G01N 33/5017 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)] | 6 Claims |
1. A method of identifying the likelihood of treating a colorectal or melanoma cancer in a subject likely to be resistant to an immune checkpoint therapy, wherein the immune checkpoint therapy comprises anti-PD-1 antibodies, anti-PD-L1 antibodies, and/or anti-PD-L2 antibodies, the method comprising:
i) selecting the subject, the subject having been identified according to:
a) obtaining or providing a sample comprising cancer cells from a subject having the cancer;
b) measuring the presence, copy number, or amount of Fbxw7 in the subject sample; and
c) comparing the presence, copy number, or amount of Fbxw7 in a control,
wherein the presence of or a significantly increased amount of wild-type Fbxw7 in the subject sample and/or the absence of or a decreased amount of Fbxw7 having a loss of function mutation in the subject sample relative to the control identifies the cancer as being likely to be responsive to the immune checkpoint therapy; and
ii) administering the immune checkpoint therapy to the selected subject.
|